For example, the dual PI3K/mTOR inhibitor PKI-587 was shown to radiosensitize HCC cells in vivo98 and combined BKM and panitumumab (human EGFR antibody) or MEK Inhibitor Binimetinib treatments showed promising results in CRC patients 99,100. Here, MTOR is linked to hepatocellular carcinoma.